PubMed:26347514 JSONTXT

{"project":"wangzhuo19_800_3","denotations":[{"id":"T1","span":{"begin":65,"end":94},"obj":"DP"},{"id":"T10","span":{"begin":441,"end":444},"obj":"CI"},{"id":"T11","span":{"begin":695,"end":698},"obj":"CI"},{"id":"T12","span":{"begin":706,"end":709},"obj":"CI"},{"id":"T13","span":{"begin":971,"end":974},"obj":"CI"},{"id":"T14","span":{"begin":1093,"end":1096},"obj":"CI"},{"id":"T15","span":{"begin":1168,"end":1171},"obj":"CI"},{"id":"T16","span":{"begin":1293,"end":1296},"obj":"CI"},{"id":"T17","span":{"begin":1405,"end":1408},"obj":"CI"},{"id":"T18","span":{"begin":223,"end":241},"obj":"CI"},{"id":"T19","span":{"begin":361,"end":379},"obj":"CI"},{"id":"T2","span":{"begin":252,"end":281},"obj":"DP"},{"id":"T20","span":{"begin":758,"end":776},"obj":"CI"},{"id":"T21","span":{"begin":243,"end":246},"obj":"CI"},{"id":"T22","span":{"begin":386,"end":389},"obj":"CI"},{"id":"T23","span":{"begin":419,"end":422},"obj":"CI"},{"id":"T24","span":{"begin":691,"end":694},"obj":"CI"},{"id":"T25","span":{"begin":935,"end":938},"obj":"CI"},{"id":"T26","span":{"begin":967,"end":970},"obj":"CI"},{"id":"T27","span":{"begin":1057,"end":1060},"obj":"CI"},{"id":"T28","span":{"begin":1089,"end":1092},"obj":"CI"},{"id":"T29","span":{"begin":1155,"end":1158},"obj":"CI"},{"id":"T3","span":{"begin":306,"end":326},"obj":"DP"},{"id":"T30","span":{"begin":1164,"end":1167},"obj":"CI"},{"id":"T31","span":{"begin":1280,"end":1283},"obj":"CI"},{"id":"T32","span":{"begin":1289,"end":1292},"obj":"CI"},{"id":"T33","span":{"begin":1401,"end":1404},"obj":"CI"},{"id":"T34","span":{"begin":1427,"end":1430},"obj":"CI"},{"id":"T35","span":{"begin":478,"end":489},"obj":"CI"},{"id":"T36","span":{"begin":550,"end":561},"obj":"CI"},{"id":"T37","span":{"begin":500,"end":511},"obj":"CI"},{"id":"T38","span":{"begin":569,"end":583},"obj":"CI"},{"id":"T39","span":{"begin":595,"end":608},"obj":"CI"},{"id":"T6","span":{"begin":11,"end":27},"obj":"CI"},{"id":"T7","span":{"begin":186,"end":202},"obj":"CI"},{"id":"T8","span":{"begin":204,"end":207},"obj":"CI"},{"id":"T9","span":{"begin":390,"end":393},"obj":"CI"}],"text":"Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial.\nBackground/Aims: To evaluate the adjuvant effects of N-acetylcysteine (NAC) on first-line sequential therapy (SQT) for Helicobacter pylori infection.\nMethods: Patients with H. pylori infections were randomly assigned to receive sequential therapy with (SQT+NAC group, n=49) or without (SQT-only group, n=50) NAC. Sequential therapy consisted of rabeprazole 20 mg and amoxicillin 1 g for the first 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg for the remaining 5 days; all drugs were administered twice daily. For the SQT+NAC group, NAC 400 mg b.i.d. was added for the first 5 days of sequential therapy. H. pylori eradication was evaluated 4 weeks after the completion of therapy.\nResults: The eradication rates by intention-to-treat analysis were 58.0% in the SQT-only group and 67.3% in the SQT+NAC group (p=0.336). The eradication rates by per-protocol analysis were 70.0% in the SQT-only group and 80.5% in the SQT+NAC group (p=0.274). Compliance was very good in both groups (SQT only/SQT+NAC groups 95.2%/100%, p=0.494). There was no significant difference in the adverse event rates between groups (SQT-only/SQT+NAC groups 26.2%/26.8%, p=0.947).\nConclusions: The H. pylori eradication rate was numerically higher in the SQT+NAC group than in the SQT-only group. As our data did not reach statistical significance, larger trials are warranted."}

{"project":"maxiaofeng52_800_3","denotations":[{"id":"T1","span":{"begin":11,"end":27},"obj":"CI"},{"id":"T10","span":{"begin":1168,"end":1171},"obj":"CI"},{"id":"T11","span":{"begin":1293,"end":1296},"obj":"CI"},{"id":"T12","span":{"begin":1405,"end":1408},"obj":"CI"},{"id":"T13","span":{"begin":223,"end":241},"obj":"CI"},{"id":"T14","span":{"begin":361,"end":379},"obj":"CI"},{"id":"T15","span":{"begin":758,"end":776},"obj":"CI"},{"id":"T16","span":{"begin":243,"end":246},"obj":"CI"},{"id":"T17","span":{"begin":386,"end":389},"obj":"CI"},{"id":"T18","span":{"begin":419,"end":422},"obj":"CI"},{"id":"T19","span":{"begin":691,"end":694},"obj":"CI"},{"id":"T2","span":{"begin":186,"end":202},"obj":"CI"},{"id":"T20","span":{"begin":935,"end":938},"obj":"CI"},{"id":"T21","span":{"begin":967,"end":970},"obj":"CI"},{"id":"T22","span":{"begin":1057,"end":1060},"obj":"CI"},{"id":"T23","span":{"begin":1089,"end":1092},"obj":"CI"},{"id":"T24","span":{"begin":1155,"end":1158},"obj":"CI"},{"id":"T25","span":{"begin":1164,"end":1167},"obj":"CI"},{"id":"T26","span":{"begin":1280,"end":1283},"obj":"CI"},{"id":"T27","span":{"begin":1289,"end":1292},"obj":"CI"},{"id":"T28","span":{"begin":1401,"end":1404},"obj":"CI"},{"id":"T29","span":{"begin":1427,"end":1430},"obj":"CI"},{"id":"T3","span":{"begin":204,"end":207},"obj":"CI"},{"id":"T30","span":{"begin":478,"end":489},"obj":"CI"},{"id":"T31","span":{"begin":550,"end":561},"obj":"CI"},{"id":"T32","span":{"begin":500,"end":511},"obj":"CI"},{"id":"T33","span":{"begin":569,"end":583},"obj":"CI"},{"id":"T34","span":{"begin":595,"end":608},"obj":"CI"},{"id":"T36","span":{"begin":252,"end":281},"obj":"DP"},{"id":"T37","span":{"begin":306,"end":326},"obj":"DP"},{"id":"T38","span":{"begin":65,"end":94},"obj":"DP"},{"id":"T4","span":{"begin":390,"end":393},"obj":"CI"},{"id":"T5","span":{"begin":441,"end":444},"obj":"CI"},{"id":"T6","span":{"begin":695,"end":698},"obj":"CI"},{"id":"T7","span":{"begin":706,"end":709},"obj":"CI"},{"id":"T8","span":{"begin":971,"end":974},"obj":"CI"},{"id":"T9","span":{"begin":1093,"end":1096},"obj":"CI"}],"text":"Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial.\nBackground/Aims: To evaluate the adjuvant effects of N-acetylcysteine (NAC) on first-line sequential therapy (SQT) for Helicobacter pylori infection.\nMethods: Patients with H. pylori infections were randomly assigned to receive sequential therapy with (SQT+NAC group, n=49) or without (SQT-only group, n=50) NAC. Sequential therapy consisted of rabeprazole 20 mg and amoxicillin 1 g for the first 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg for the remaining 5 days; all drugs were administered twice daily. For the SQT+NAC group, NAC 400 mg b.i.d. was added for the first 5 days of sequential therapy. H. pylori eradication was evaluated 4 weeks after the completion of therapy.\nResults: The eradication rates by intention-to-treat analysis were 58.0% in the SQT-only group and 67.3% in the SQT+NAC group (p=0.336). The eradication rates by per-protocol analysis were 70.0% in the SQT-only group and 80.5% in the SQT+NAC group (p=0.274). Compliance was very good in both groups (SQT only/SQT+NAC groups 95.2%/100%, p=0.494). There was no significant difference in the adverse event rates between groups (SQT-only/SQT+NAC groups 26.2%/26.8%, p=0.947).\nConclusions: The H. pylori eradication rate was numerically higher in the SQT+NAC group than in the SQT-only group. As our data did not reach statistical significance, larger trials are warranted."}